Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
List view / Grid view
In this guide, we discuss the things you should consider as part of your business case when purchasing automated liquid handling equipment.
Download this whitepaper to discover the latest research and developments in cell and gene therapies via exclusive articles and interviews.
This whitepaper overviews use of Advanced Flow Cytometry to accelerate antibody screening and characterisation and reveal deeper biological insights.
This whitepaper describes several live-cell phenotypic analyses suitable for the characterisation of astroglia cells.
Accelerate the discovery process of new drugs and targets with a better understanding of the metabolome and lipidome during drug development.
The cell painting assay uses up to six fluorescent dyes to label and visualize a variety of subcellular structures at the single cell level.
The latest edition of the live-cell analysis handbook is a companion guide for live-cell analysis users. Includes discussion of live-cell analysis.
This whitepaper overviews the importance of understanding T Cell Biology to build better therapeutics, demonstrates use of advanced flow cytometry.
Depletion of ATP due to viral-induced CPE leads to a reduction in luminescence signal, enabling quantitation of viral-induced CPE in host cells.
Cell Line Development and cell culture process teams, are you geared up to leverage the vast amount of data generated by high-throughput?
Application note: High-throughput IgG quantitation platform for clone screening during drug discovery and development
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
Examining existing R&D processes with a consolidated approach enables the stop of disjointed workflows to engage on the digitisation journey.
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.